{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:06:48Z","timestamp":1763003208971,"version":"3.45.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":476,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015542","name":"GlaxoSmithKline Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002424","name":"Fujifilm Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013172","name":"SymBio Pharmaceuticals Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jtct.2021.10.021","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T21:21:03Z","timestamp":1636579263000},"page":"76-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-9113","authenticated-orcid":false,"given":"Shin-ichi","family":"Fuchida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ohkawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9653-6170","authenticated-orcid":false,"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-7125","authenticated-orcid":false,"given":"Shinya","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-0620","authenticated-orcid":false,"given":"Ken","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4487-5808","authenticated-orcid":false,"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5498-3370","authenticated-orcid":false,"given":"Yukinori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0393-4066","authenticated-orcid":false,"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.10.021_bib0001","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only","volume":"100","author":"Skinner","year":"1996","journal-title":"Am J Med."},{"key":"10.1016\/j.jtct.2021.10.021_bib0002","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2007-02-076034","article-title":"Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis","volume":"110","author":"Palladini","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.jtct.2021.10.021_bib0003","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.10.021_bib0004","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.bmt.1704691","article-title":"Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate","volume":"34","author":"Gertz","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jtct.2021.10.021_bib0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.jtct.2021.10.021_bib0006","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/sj.leu.2401593","article-title":"Autologous stem cell transplantation for AL amyloidosis: a standard therapy?","volume":"13","author":"Moreau","year":"1999","journal-title":"Leukemia."},{"key":"10.1016\/j.jtct.2021.10.021_bib0007","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/bmt.2010.234","article-title":"Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006","volume":"46","author":"Gertz","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jtct.2021.10.021_bib0008","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research study","volume":"33","author":"D'Souza","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.jtct.2021.10.021_bib0009","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12185-015-1922-x","article-title":"High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases","volume":"103","author":"Tsukada","year":"2016","journal-title":"Int J Hematol."},{"key":"10.1016\/j.jtct.2021.10.021_bib0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2169\/internalmedicine.9206-17","article-title":"Nationwide survey of 741 patients with systemic amyloid light-chain amyloidosis in Japan","volume":"57","author":"Shimazaki","year":"2018","journal-title":"Intern Med."},{"key":"10.1016\/j.jtct.2021.10.021_bib0011","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1532\/IJH97.06239","article-title":"Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System","volume":"86","author":"Atsuta","year":"2007","journal-title":"Int J Hematol."},{"key":"10.1016\/j.jtct.2021.10.021_bib0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol."},{"key":"10.1016\/j.jtct.2021.10.021_bib0013","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.jtct.2021.10.021_bib0014","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.10.021_bib0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4065\/83.3.297","article-title":"Serum uric acid: novel prognostic factor in primary systemic amyloidosis","volume":"83","author":"Kumar","year":"2008","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.jtct.2021.10.021_bib0016","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.jtct.2021.10.021_bib0017","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med."},{"key":"10.1016\/j.jtct.2021.10.021_bib0018","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat."},{"key":"10.1016\/j.jtct.2021.10.021_bib0019","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jtct.2021.10.021_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","article-title":"Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation","volume":"103","author":"Kanda","year":"2016","journal-title":"Int J Hematol."},{"key":"10.1016\/j.jtct.2021.10.021_bib0021","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.jtct.2021.10.021_bib0022","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of immunoglobulin light chain amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.jtct.2021.10.021_bib0023","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","article-title":"Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis; a report on 21 patients","volume":"101","author":"Moreau","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.10.021_bib0024","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2001.19.14.3350","article-title":"Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival","volume":"19","author":"Dispenzieri","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.jtct.2021.10.021_bib0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2007.06936.x","article-title":"Perspectives in treatment of AL amyloidosis","volume":"140","author":"Wechalekar","year":"2008","journal-title":"Br J Haematol."},{"key":"10.1016\/j.jtct.2021.10.021_bib0026","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/bmt.2013.53","article-title":"Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center","volume":"48","author":"Dispenzieri","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jtct.2021.10.021_bib0027","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjh.12673","article-title":"Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution","volume":"164","author":"Jimenez-Zepeda","year":"2014","journal-title":"Br J Haematol."},{"key":"10.1016\/j.jtct.2021.10.021_bib0028","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood.V99.12.4276","article-title":"Autologous stem cell transplantation for primary systemic amyloidosis","volume":"99","author":"Comenzo","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.jtct.2021.10.021_bib0029","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bmt.2017.68","article-title":"Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival","volume":"52","author":"Tandon","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jtct.2021.10.021_bib0030","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.jtct.2021.10.021_bib0031","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1038\/bcj.2015.34","article-title":"Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death","volume":"5","author":"Warsame","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jtct.2021.10.021_bib0032","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.jtct.2021.10.021_bib0033","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/0148607113501328","article-title":"Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment","volume":"38","author":"Caccialanza","year":"2014","journal-title":"JPEN J Parenter Enteral Nutr."},{"key":"10.1016\/j.jtct.2021.10.021_bib0034","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.bbmt.2018.07.010","article-title":"Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic stem cell transplantation","volume":"24","author":"Afrough","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.jtct.2021.10.021_bib0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.10.021_bib0036","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomized, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721013610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721013610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:02:32Z","timestamp":1763002952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721013610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2666636721013610"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.10.021","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}